Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/653
Login to MRSPTU Repository
DC FieldValueLanguage
dc.contributor.authorMachhi, J-
dc.contributor.authorShahjin, F-
dc.contributor.authorDas, S-
dc.contributor.authorPatel, M-
dc.contributor.authorCohen, J D-
dc.contributor.authorSingh, P A-
dc.contributor.authorBaldi, A-
dc.contributor.authorBajwa, N-
dc.contributor.authorKumar, R-
dc.contributor.authorVora, L K-
dc.date.accessioned2023-07-18T06:54:35Z-
dc.date.available2023-07-18T06:54:35Z-
dc.date.issued2021-
dc.identifier.issn1872-8294-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0169409X21000028?via%3Dihub-
dc.description.abstractThe SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.en_US
dc.language.isoenen_US
dc.publisherAdvanced Drug Delivery Reviews,171en_US
dc.subjectNanocarrier vaccinesen_US
dc.subjectSARS-CoV-2en_US
dc.titleNanocarrier vaccines for SARS-CoV-2en_US
dc.typeArticleen_US
Appears in Collections:Research Papers

Login to MRSPTU Repository
There are no files associated with this item.


Items in MRSPTU Repository are protected by copyright, with all rights reserved, unless otherwise indicated.